Clinical Trial: Efficacy and Safety of DA-3002 in Children With Idiopathic Short Stature
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Open, Multi-Center, Controlled, Randomized Phase III Clinical Trial to Evaluate the Efficacy and Safety of DA-3002(Recombinant Humn Growth Hormone)Treatment in Children With Idiopathic Same as current
Current Secondary Outcome: Difference of Height Standard Deviation Score Between Treatment and Non-treatment Group After 26 Weeks [ Time Frame: 26 weeks ]
Original Secondary Outcome: Difference of Height Standard Deviation Score Between Treatment and Non-treatment Group After 26 Weeks [ Time Frame: 26 weeks ]
Information By: Dong-A ST Co., Ltd.
Dates:
Date Received: February 6, 2013
Date Started: February 2012
Date Completion:
Last Updated: May 11, 2015
Last Verified: May 2015